Cargando…
Open transcatheter valve implantation for mitral annular calcification: One-year outcomes
BACKGROUND: Transcatheter mitral valve implantation (TMVI) for native mitral valve pathology with severe mitral annular calcification has emerged as an alternative treatment option to conventional mitral valve surgery. The objective of this study was to evaluate patients who were referred for TMVI w...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691218/ https://www.ncbi.nlm.nih.gov/pubmed/34977731 http://dx.doi.org/10.1016/j.xjtc.2021.08.004 |
_version_ | 1784618761130606592 |
---|---|
author | Hamid, Umar Imran Gregg, Anne Ball, Peter Owens, Colum Manoharan, Ganesh Spence, Mark S. Jeganathan, Reuben |
author_facet | Hamid, Umar Imran Gregg, Anne Ball, Peter Owens, Colum Manoharan, Ganesh Spence, Mark S. Jeganathan, Reuben |
author_sort | Hamid, Umar Imran |
collection | PubMed |
description | BACKGROUND: Transcatheter mitral valve implantation (TMVI) for native mitral valve pathology with severe mitral annular calcification has emerged as an alternative treatment option to conventional mitral valve surgery. The objective of this study was to evaluate patients who were referred for TMVI with severe mitral annular calcification and their procedural outcomes. METHODS: Retrospective analysis of patients from 2017 to 2020 referred for TMVI was carried out. Demographic characteristic details; surgical strategy; perioperative complications; and hospital stay, including 30-day and 1-year mortality, were analyzed. RESULTS: Eleven patients were referred for consideration of TMVI. The 8 patients who underwent TMVI had a median age of 74 years (range, 57-80 years), the median Society of Thoracic Surgeons score was 4.6 (range, 2.4-10.9), and European System for Cardiac Operative Risk Evaluation II score was 5.2% (2%-10.1%). The median cardiopulmonary bypass time and crossclamp times were 170 minutes (range, 150-248 minutes) and 152 minutes (range, 118-214 minutes), respectively. The median hospital stay was 29 days (range, 2-40 days). Thirty-day in hospital mortality was 12%, whereas 1-year mortality was 25%. There was symptomatic improvement with downgrade of New York Heart Association functional class from III or IV to I or II. The 3 patients who were turned down had a median age of 73 years, median Society of Thoracic Surgeons score was 13.4, and median European System for Cardiac Operative Risk Evaluation II score was 5.72%. They were alive at 12 months follow-up from the date of surgical assessment; however, all with New York Heart Association functional class III or IV symptoms. CONCLUSIONS: We describe a series demonstrating the technical consideration and capability of transatrial TMVI to treat mitral annular calcification and native mitral valve disease. Our results are favorable when compared with TMVI global registry data for transseptal or transapical approach. |
format | Online Article Text |
id | pubmed-8691218 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-86912182021-12-30 Open transcatheter valve implantation for mitral annular calcification: One-year outcomes Hamid, Umar Imran Gregg, Anne Ball, Peter Owens, Colum Manoharan, Ganesh Spence, Mark S. Jeganathan, Reuben JTCVS Tech Adult: Mitral Valve: Evolving Technology BACKGROUND: Transcatheter mitral valve implantation (TMVI) for native mitral valve pathology with severe mitral annular calcification has emerged as an alternative treatment option to conventional mitral valve surgery. The objective of this study was to evaluate patients who were referred for TMVI with severe mitral annular calcification and their procedural outcomes. METHODS: Retrospective analysis of patients from 2017 to 2020 referred for TMVI was carried out. Demographic characteristic details; surgical strategy; perioperative complications; and hospital stay, including 30-day and 1-year mortality, were analyzed. RESULTS: Eleven patients were referred for consideration of TMVI. The 8 patients who underwent TMVI had a median age of 74 years (range, 57-80 years), the median Society of Thoracic Surgeons score was 4.6 (range, 2.4-10.9), and European System for Cardiac Operative Risk Evaluation II score was 5.2% (2%-10.1%). The median cardiopulmonary bypass time and crossclamp times were 170 minutes (range, 150-248 minutes) and 152 minutes (range, 118-214 minutes), respectively. The median hospital stay was 29 days (range, 2-40 days). Thirty-day in hospital mortality was 12%, whereas 1-year mortality was 25%. There was symptomatic improvement with downgrade of New York Heart Association functional class from III or IV to I or II. The 3 patients who were turned down had a median age of 73 years, median Society of Thoracic Surgeons score was 13.4, and median European System for Cardiac Operative Risk Evaluation II score was 5.72%. They were alive at 12 months follow-up from the date of surgical assessment; however, all with New York Heart Association functional class III or IV symptoms. CONCLUSIONS: We describe a series demonstrating the technical consideration and capability of transatrial TMVI to treat mitral annular calcification and native mitral valve disease. Our results are favorable when compared with TMVI global registry data for transseptal or transapical approach. Elsevier 2021-08-10 /pmc/articles/PMC8691218/ /pubmed/34977731 http://dx.doi.org/10.1016/j.xjtc.2021.08.004 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Adult: Mitral Valve: Evolving Technology Hamid, Umar Imran Gregg, Anne Ball, Peter Owens, Colum Manoharan, Ganesh Spence, Mark S. Jeganathan, Reuben Open transcatheter valve implantation for mitral annular calcification: One-year outcomes |
title | Open transcatheter valve implantation for mitral annular calcification: One-year outcomes |
title_full | Open transcatheter valve implantation for mitral annular calcification: One-year outcomes |
title_fullStr | Open transcatheter valve implantation for mitral annular calcification: One-year outcomes |
title_full_unstemmed | Open transcatheter valve implantation for mitral annular calcification: One-year outcomes |
title_short | Open transcatheter valve implantation for mitral annular calcification: One-year outcomes |
title_sort | open transcatheter valve implantation for mitral annular calcification: one-year outcomes |
topic | Adult: Mitral Valve: Evolving Technology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691218/ https://www.ncbi.nlm.nih.gov/pubmed/34977731 http://dx.doi.org/10.1016/j.xjtc.2021.08.004 |
work_keys_str_mv | AT hamidumarimran opentranscathetervalveimplantationformitralannularcalcificationoneyearoutcomes AT gregganne opentranscathetervalveimplantationformitralannularcalcificationoneyearoutcomes AT ballpeter opentranscathetervalveimplantationformitralannularcalcificationoneyearoutcomes AT owenscolum opentranscathetervalveimplantationformitralannularcalcificationoneyearoutcomes AT manoharanganesh opentranscathetervalveimplantationformitralannularcalcificationoneyearoutcomes AT spencemarks opentranscathetervalveimplantationformitralannularcalcificationoneyearoutcomes AT jeganathanreuben opentranscathetervalveimplantationformitralannularcalcificationoneyearoutcomes |